Suppr超能文献

高龄房颤患者的血栓栓塞风险、出血结局及不同抗栓策略的效果:来自房颤预防试验(预防血栓栓塞事件-欧洲房颤注册研究)的亚组分析

Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (vention o Thromboembolic Events-uropean egistry in trial ibrillation).

作者信息

Patti Giuseppe, Lucerna Markus, Pecen Ladislav, Siller-Matula Jolanta M, Cavallari Ilaria, Kirchhof Paulus, De Caterina Raffaele

机构信息

Department of Cardiovascular Sciences, Campus Bio-Medico University of Rome, Italy

Daiichi Sankyo Europe, Munich, Germany.

出版信息

J Am Heart Assoc. 2017 Jul 23;6(7):e005657. doi: 10.1161/JAHA.117.005657.

Abstract

BACKGROUND

Increasing age predisposes to both thromboembolic and bleeding events in patients with atrial fibrillation; therefore, balancing risks and benefits of antithrombotic strategies in older populations is crucial. We investigated 1-year outcome with different antithrombotic approaches in very elderly atrial fibrillation patients (age ≥85 years) compared with younger patients.

METHODS AND RESULTS

We accessed individual patients' data from the prospective PREFER in AF (PREvention oF thromboembolic events-European Registry in Atrial Fibrillation), compared outcomes with and without oral anticoagulation (OAC), and estimated weighed net clinical benefit in different age groups. A total of 6412 patients, 505 of whom were aged ≥85 years, were analyzed. In patients aged <85 years, the incidence of thromboembolic events was 2.8%/year without OAC versus 2.3%/year with OAC (0.5% absolute reduction); in patients aged ≥85 years, it was 6.3%/year versus 4.3%/year (2% absolute reduction). In very elderly patients, the risk of major bleeding was higher than in younger patients, but similar in patients on OAC and in those on antiplatelet therapy or without antithrombotic treatment (4.0%/year versus 4.2%/year; =0.77). OAC was overall associated with weighted net clinical benefit, assigning weights to nonfatal events according to their prognostic implication for subsequent death (-2.19%; CI, -4.23%, -0.15%; =0.036). We found a significant gradient of this benefit as a function of age, with the oldest patients deriving the highest benefit.

CONCLUSIONS

Because the risk of stroke increases with age more than the risk of bleeding, the absolute benefit of OAC is highest in very elderly patients, where it, by far, outweighs the risk of bleeding, with the greatest net clinical benefit in such patients.

摘要

背景

年龄增长使房颤患者发生血栓栓塞事件和出血事件的风险增加;因此,在老年人群中平衡抗栓策略的风险和获益至关重要。我们研究了与年轻患者相比,采用不同抗栓方法治疗高龄房颤患者(年龄≥85岁)的1年结局。

方法与结果

我们从房颤预防(PREvention oF thromboembolic events-European Registry in Atrial Fibrillation,PREFER in AF)前瞻性研究中获取个体患者数据,比较接受和未接受口服抗凝治疗(OAC)的结局,并评估不同年龄组的加权净临床获益。共分析了6412例患者,其中505例年龄≥85岁。在年龄<85岁的患者中,未接受OAC时血栓栓塞事件的发生率为每年2.8%,接受OAC时为每年2.3%(绝对降低0.5%);在年龄≥85岁的患者中,分别为每年6.3%和4.3%(绝对降低2%)。在高龄患者中,大出血风险高于年轻患者,但接受OAC治疗的患者、接受抗血小板治疗的患者或未接受抗栓治疗的患者中大出血风险相似(每年4.0%对4.2%;P=0.77)。OAC总体上与加权净临床获益相关,根据非致命事件对后续死亡的预后影响赋予权重(-2.19%;95%CI,-至4.23%,-0.15%;P=0.036)。我们发现这种获益随着年龄增长呈显著梯度变化,年龄最大的患者获益最高。

结论

由于卒中风险随年龄增长的幅度超过出血风险,OAC在高龄患者中的绝对获益最高,在这类患者中,OAC的获益远超过出血风险,净临床获益最大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64a6/5586290/c298c359ca91/JAH3-6-e005657-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验